1518P Zanidatamab (zani) plus chemotherapy (chemo) and tislelizumab (tis) as first-line (1l) therapy for patients (pts) with advanced HER2-positive (+) gastric/gastroesophageal junction adenocarcinoma (GC/GEJC): Updated results from a phase Ib/II study

Kyung-Woo Lee(Konkuk University), Y-K. Kang(Asan Medical Center), Yee Chao(National Cancer Center), Jieer Ying(Chinese Academy of Medical Sciences & Peking Union Medical College), Sang Cheul Oh(Korea University), L-Y. Bai(China Medical University), Y. Bao(Chinese Academy of Medical Sciences & Peking Union Medical College), Y. Choi(Beth Israel Deaconess Medical Center), Y-H Im(Samsung Medical Center), D-Y. Oh(Seoul National University Hospital), Minkyu Jung(Cancer Research Institute)
Annals of Oncology
October 1, 2023
10.1016/j.annonc.2023.09.1431
Cited by 8

Related Papers

Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k
Hepatogastroenterology
|Hepatogastroenterology|2012|1.3k
Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial
|The Lancet Oncology|2013|838
Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
|Journal of Clinical Oncology|2013|775
Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study
|Journal of Clinical Oncology|2013|596